Łomianki, Poland
Łomianki, Poland

Time filter

Source Type

News Article | December 16, 2016
Site: marketersmedia.com

— Huntington Disease - Companies Involved in Therapeutics Development are Addex Therapeutics Ltd, AFFiRiS AG, Angita BV, Annexon Inc, Astellas Pharma Inc, Azevan Pharmaceuticals Inc, BioCrea GmbH, BrainStorm Cell Therapeutics Inc, Celon Pharma Sp z oo, Chong Kun Dang Pharmaceutical Corp, Diffusion Pharmaceuticals Inc, EncephRx Inc, Evotec AG, Galenea Corp, Genervon Biopharmaceuticals LLC, Horizon Pharma Plc, Immungenetics AG, Ionis Pharmaceuticals Inc, Ipsen SA, Kadmon Corp LLC, KineMed Inc, Krenitsky Pharmaceuticals Inc, Living Cell Technologies Ltd, Medesis Pharma SA, Mitochon Pharmaceuticals Inc, Neuralstem Inc, Neurimmune Holding AG, NeuroNascent Inc, New World Laboratories Inc, nLife Therapeutics SL, NsGene A/S, Omeros Corp, Oryzon Genomics SA, Pfizer Inc, PharmatrophiX Inc, ProQR Therapeutics NV, QR Pharma Inc, reMYND NV, Retrotope Inc, Rhenovia Pharma Ltd, Shire Plc, SOM Biotech SL, Spark Therapeutics Inc, Teva Pharmaceutical Industries Ltd, TyrNovo Ltd, Ultragenyx Pharmaceutical Inc, UniQure NV, Vaccinex Inc, Vertex Pharmaceuticals Inc, VistaGen Therapeutics Inc, Vitality Biopharma Inc, VivaCell Biotechnology Espana SL, Voyager Therapeutics Inc, Vybion Inc, WAVE Life Sciences Ltd and Wellstat Therapeutics Corp. Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow. The Huntington Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 10, 5, 46 and 17 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 19 and 4 molecules, respectively. Huntington Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Inquire more about this report at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=786898 Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. • The pipeline guide provides a snapshot of the global therapeutic landscape of Huntington Disease (Central Nervous System). • The pipeline guide reviews pipeline therapeutics for Huntington Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Huntington Disease (Central Nervous System) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Huntington Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Huntington Disease (Central Nervous System) • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Huntington Disease (Central Nervous System). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Huntington Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. For more information, please visit http://www.reportsnreports.com/reports/786898-huntington-disease-pipeline-review-h2-2016.html


News Article | November 11, 2016
Site: www.newsmaker.com.au

The report provides comprehensive information on the therapeutics under development for Asthma ,complete with analysis by stage of development, drug target, mechanism of action (MoA),route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Asthma and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Asthma - Pipeline Review,H2 2016 addition with 218 market data tables and 17 figures, spread across 735 pages is available at http://www.rnrmarketresearch.com/asthma-pipeline-review-h2-2016-market-report.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries,conferences,SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Asthma - Companies Involved in Therapeutics Development,4D Pharma Plc ,AB Science SA ,AbbVie Inc ,Abeome Corporation,Accolade Pharmaceuticals, LLCAcorda Therapeutics, Inc.,Adamis Pharmaceuticals Corporation,Bioncotech Therapeutics SL,Biotec Pharmacon ASA,Boehringer Ingelheim GmbH,CalciMedica, Inc. ,Cellceutix Corporation,Cellular Biomedicine Group, Inc.,Celon Pharma Sp. z o.o.,Chiesi Farmaceutici SpA,Circassia Pharmaceuticals Plc,Cognosci, Inc. Inquire before buying http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=748008(This is a premium report price at US$2000 for a single user PDF license).


Mazur M.,Celon Pharma | Mazur M.,Medical University of Lódz | Bujak A.,Celon Pharma | Matloka M.,Celon Pharma | And 9 more authors.
Analytical Biochemistry | Year: 2015

Deregulation of the Wnt/β-catenin signaling pathway is associated with many serious disorders, including cancer and Alzheimer's disease. The pivotal player is β-catenin, which avoids degradation after activation of the pathway and is translocated to the nucleus, where it interacts with TCF/LEF transcription factors and induces expression of genes involved in cell cycle and apoptosis regulation. The identification of small molecules that may affect Wnt/β-catenin signaling remains an important target during the development of novel therapies. We used the TCF/LEF lentiviral vector and the Wnt-independent H1703 cell line to develop a luciferase reporter-based cell assay for screening of the Wnt/β-catenin pathway modulators. Following the optimization of cell density, concentration of activator, and stimulation time, the reporter system was validated by demonstrating its specific and dose-dependent response to several established modulators of Wnt/β-catenin signaling such as Wnt3a, small interfering RNA (siRNA) against β-catenin, glycogen synthase kinase 3 (GSK-3), and β-catenin/TCF transcription complex inhibitors. Two pilot screens of inhibitors and activators of Wnt/β-catenin signaling identified potential novel modulators of this pathway. Our findings suggest that the H1703-7TFP assay constitutes a suitable model of low background and high sensitivity for the low- and high-scale screening of the Wnt/β-catenin pathway modulators. © 2015 Elsevier Inc. All rights reserved.


Paczkowska E.,Celon Pharma | Smukowska D.,Celon Pharma | Tratkiewicz E.,Celon Pharma | Bialasiewicz P.,Medical University of Lódz
Acta Chromatographica | Year: 2015

A simple and accurate reversed phase high-performance liquid chromatography (HPLC) method has been developed for the estimation of uniformity of dosage units, and delivered dose uniformity tests of fluticasone propionate and salmeterol xinafoate in samples obtained during the fine particle mass determination, using C8 Luna (2) 100A 100 x 4.6 mm, 5 micrometer particle size in gradient mode, with mobile phase comprising of buffer solution: 0.6% trifluoroacetic acid solution in water- Tetrahydrofurane (8:2 v/v) and acetonitrile-methanol (1:1 v/v) in the ratio of 60:40 v/v. The flow rate was 1.5 mL min-1, and the detection was monitored by ultraviolet (UV) detector at 239 nm and 250 nm. Linearity was observed in the concentration range of 0.025- 4.8μg mL-1 for salmeterol xinafoate and 0.04-32.5 μg mL-1 for fluticasone propionate (R2 > 0.999). The recovery in the range from 98.2% to 102.7% and relative standard deviation (RSD) ≤ 2.2% demonstrated accuracy and high precision of the method. The quantification limit at an injection volume of 40 μL was 0.04 μg mL-1 for fluticasone propionate and 0.025 μg mL-1 for salmeterol xinafoate. The developed and validated method can be successfully applied for simultaneous quality control of dry powder inhalation products containing salmeterol xinafoate and fluticasone propionate in pharmaceutical industry.


PubMed | Nencki Institute of Experimental Biology, Medical University of Lódz and Celon Pharma
Type: | Journal: Analytical biochemistry | Year: 2015

Deregulation of the Wnt/-catenin signaling pathway is associated with many serious disorders, including cancer and Alzheimers disease. The pivotal player is -catenin, which avoids degradation after activation of the pathway and is translocated to the nucleus, where it interacts with TCF/LEF transcription factors and induces expression of genes involved in cell cycle and apoptosis regulation. The identification of small molecules that may affect Wnt/-catenin signaling remains an important target during the development of novel therapies. We used the TCF/LEF lentiviral vector and the Wnt-independent H1703 cell line to develop a luciferase reporter-based cell assay for screening of the Wnt/-catenin pathway modulators. Following the optimization of cell density, concentration of activator, and stimulation time, the reporter system was validated by demonstrating its specific and dose-dependent response to several established modulators of Wnt/-catenin signaling such as Wnt3a, small interfering RNA (siRNA) against -catenin, glycogen synthase kinase 3 (GSK-3), and -catenin/TCF transcription complex inhibitors. Two pilot screens of inhibitors and activators of Wnt/-catenin signaling identified potential novel modulators of this pathway. Our findings suggest that the H1703-7TFP assay constitutes a suitable model of low background and high sensitivity for the low- and high-scale screening of the Wnt/-catenin pathway modulators.

Loading Celon Pharma collaborators
Loading Celon Pharma collaborators